Efficacy and Safety of Argatroban and Bivalirudine in Patients with Suspected Heparin-Induced Thrombocytopenia

Annals of Pharmacotherapy

Volumn 49, Issue 2, 2015, Pages 178-184

  Vo, Quynh Anh T ^a   Lin, Joyce K ^b   Tong, Lisa M ^b  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

anticoagulation; argatroban; bivalirudin; direct thrombin inhibitors; heparin induced thrombocytopenia

Indexed keywords

ARGATROBAN; HIRULOG; WARFARIN; ANTICOAGULANT AGENT; HEPARIN; HIRUDIN DERIVATIVE; PEPTIDE FRAGMENT; PIPECOLIC ACID DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; KIDNEY FUNCTION; LIMB AMPUTATION; LIVER DYSFUNCTION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MORTALITY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; SEROTONIN RELEASE; THROMBOEMBOLISM; TREATMENT DURATION; CHEMICALLY INDUCED; HEMORRHAGE; MIDDLE AGED; RETROSPECTIVE STUDY; THROMBOCYTOPENIA;

AGED; ANTICOAGULANTS; FEMALE; HEMORRHAGE; HEPARIN; HIRUDINS; HUMANS; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PEPTIDE FRAGMENTS; PIPECOLIC ACIDS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA;

EID: 84920982451     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028014562949     Document Type: Article

References (21)

1. Warkentin TE,Sheppard JI.Generation of platelet-derived microparticles and procoagulant activity by heparin-induced thrombocytopenia IgG/serum and other IgG platelet agonists: a comparison with standard platelet agonists.Platelets. 1999;10:319-326
2. Martel N,Lee J,Wells PS.Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis.Blood. 2005;106:2710
3. Linkins LA,Dans AL,Moores LK, et al.Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines.Chest. 2012;141:e495S-e530S
4. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc; 2010:
5. Research Triangle Park, NC: GlaxoSmithKline; 2012:
6. West Orange, NJ: Organon Inc; 1998:
7. Mayo Clinic. Danaparoid (subcutaneous route). http://www.mayoclinic.com/health/drug-information/DR600517. Accessed July 25, 2013.
8. US Department of Health and Human Services Health Resources and Service Information. http://www.hrsa.gov/opa/programrequirements/manufacturerletters/2012/refludan05312012.pdf. May2012.
9. Francis J,Drexler A,Gwyn G, et al.Bivalirudin, a direct thrombin inhibitor, is a safe and effective treatment for heparin-induced thrombocytopenia [abstract].Blood. 2003;102:164a
10. Dang CH,Durkalski VL,Nappi JM.Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia.Pharmacotherapy. 2006;26:461-468
11. Kiser TH,Burch JC,Klem PM, et al.Safety, efficacy, and dosing requirements of bivalirudin in patients with heparin-induced thrombocytopenia.Pharmacotherapy. 2008;28:1115-1124
12. Skrupky LP,Smith JR,Deal EN, et al.Comparison of bivalirudin and argatroban for the management of heparin-induced thrombocytopenia.Pharmacotherapy. 2010;30:1229-1238
13. Tsu LV,Dager WE.Bivalirudin dosing adjustments for reduced renal function with or without hemodialysis in the management of heparin-induced thrombocytopenia.Ann Pharmacother. 2011;45:1185-1192
14. Runyan CL,Cabral KP,Riker RR, et al.Correlation of bivalirudin dose with creatinine clearance during treatment of heparin-induced thrombocytopenia.Pharmacotherapy. 2011;31:850-856
15. Parsippany, NJ: Medicines Company; 2012:
16. Gosselin RC,Dager WE,King JH, et al.Effect of direct thrombin inhibitors, bivalirudin, lepirudin, and argatroban on prothrombin time and INR values.Am J Clin Pathol. 2004;121:593-599
17. Lewis BE,Wallis DE,Leya F, et al.Argatroban anticoagulation in patients with heparin-induced thrombocytopenia.Arch Intern Med. 2003;163:1849-1856
18. Kiser TH,Jung R,MacLaren R, et al.Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia.Pharmacotherapy. 2005;25:1736-1745
19. Hursting MJ,Soffer J.Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in heparin-induced thrombocytopenia.Drug Saf. 2009;32:203-218
20. Lewis BE,Wallis DE,Berkowitz SD, et al.Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia.Circulation. 2001;103:1838-1843
21. Lubenow N,Eicher P,Lietz T, et al.Lepirudin in patients with heparin induced thrombocytopenia: results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3.J Thromb Haemost. 2005;3:2428-2436